Lian Duan

Dr. Lian Duan


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Molecular BioSystems
Verified
Journal Article
Closed access
PDF file
LDLian Duan
Lian Duan
XXXingjiang Xiong
Xingjiang Xiong
YLYongmei Liu
Yongmei Liu
JWJie Wang
Jie Wang
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules consisting of 19–22 nucleotides that play an important role in a variety of biological processes, including development, differentiation, apoptosis, cell proliferation and cellular senescence. A growing body of evidence suggests that miRNAs are aberrantly expressed in human cardiac diseases and they play a significant role in the initiation and development. Recently, studies revealed that microRNA-1 (miR-1) was frequently downregulated in various types of cardiac diseases. Here we review recent findings on the aberrant expression and functional significance of miR-1.

1 July 2018 in Trends in Cardiovascular Medicine
Verified
Journal Article
Closed access
LDLian Duan
Lian Duan
CLChao Liu
Chao Liu
JHJunyuan Hu
Junyuan Hu
YLYongmei Liu
Yongmei Liu
JWJie Wang
Jie Wang
HCHengwen Chen
Hengwen Chen

1 August 2018 in Phytomedicine
Verified
Journal Article
Closed access
LDLian Duan
Lian Duan
XXXingjiang Xiong
Xingjiang Xiong
JHJunyuan Hu
Junyuan Hu
YLYongmei Liu
Yongmei Liu
JWJie Wang
Jie Wang

9 June 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
LLLan-Chun Liu
Lan-Chun Liu
QMQi-Yuan Mao
Qi-Yuan Mao
CLChao Liu
Chao Liu
JHJun Hu
Jun Hu
LDLian Duan
Lian Duan
JWJie Wang
Jie Wang
Objective. The aim of this meta-analysis was to systematically evaluate the effectiveness and safety of the traditional Chinese medicine (TCM) formula Bushen Huoxue Decoction (BSHXD) in treating coronary heart disease (CHD). Methods. Randomized controlled trials (RCTS) of BSHXD in treating CHD were searched until March 2020, through six electronic databases: PubMed, Cochrane Library, CNKI, WanFang, SinoMed, and VIP. This study used the Cochrane Risk Test bias tool in the Cochrane Handbook to assess the quality of the methodology. Review Manager (RevMan) 5.3 was used to analyze the results. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria were applied in the classification of evidence quality. Results. Ten RCTs involving 901 patients were finally included in this meta-analysis. It revealed that the effectiveness of BSHXD in treating CHD was significantly better than that of the conventional western medicine (CWM) treatment ( ). The effective rate of BSHXD treatment group on ECG was also significantly higher than that of CWM group ( ). The low-density lipoprotein cholesterol was decreased in the treatment groups compared with those in the control groups ( ). There was also a reduction in frequency and duration of angina pectoris ( ). There were no significant differences in TC level ( ), TG level ( ), and HDL level ( ) between the treatment and control groups. Five studies had informed adverse events, including nausea and diarrhea. Conclusion. Our findings laid the foundation to the use of TCM Formula BSHXD in combination with conventional western medicine for treating CHD. However, due to the limitation of the quality of the included researches, in addition to potential reporting bias, the above conclusions still need verification by higher-quality and better-designed studies.

1 December 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
JWJie Wang
Jie Wang
YDYan Dong
Yan Dong
ZLZhaoling Li
Zhaoling Li
YZYun Zhang
Yun Zhang
LLLanchun Liu
Lanchun Liu
LDLian Duan
Lian Duan
Background: Improving angiogenesis in the ischemic myocardium is a therapeutic strategy for preventing, reducing, and repairing myocardial injury of coronary artery disease (CAD). Panax notoginseng saponins (PNS) have been widely used in the clinical treatment of cardiovascular diseases, demonstrating excellent efficacy, and can potentially improve angiogenesis in the ischemic myocardium. However, the effects of PNS on angiogenesis and its underlying mechanism of action remain unclear. Purpose: In this study, we aimed to evaluate the role of PNS in improving angiogenesis after myocardial infarction (MI) and explain the mechanism of PNS in improving angiogenesis in CAD from an epigenetic perspective. Study Design: The MI rat model was established by ligating the left anterior descending coronary artery permanently. The in vitro model comprised hypoxic human coronary artery endothelial cells (HCEACs). The mice and cells were then treated with PNS. Methods: Blood tests, histomorphology, polymerase chain reaction, enzyme-linked immunosorbent assay, Western blotting, and MassARRAY targeted methylation detection analyses were conducted in vivo and in vitro to investigate the potential mechanisms of PNS. Results: Oral PNS significantly improved myocardial injury and activated angiogenesis in MI rats. DNA methylation analysis in vitro revealed that PNS decreased the hypermethylation of microRNA 200a (miR200a). PNS improved angiogenesis in hypoxic human coronary artery endothelial cells (HCEACs) by regulating the vascular endothelial growth factor (VEGF) pathway. Conclusion: Our research shows that PNS can improve angiogenesis in rats with MI and hypoxic HCEACs and affect the level of miR200a promoter methylation and miR200a and VEGF molecular pathways.